Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Niemann-Pick C1-like 1 (NPC1L1) . Interestingly, NPC1L1 is abundantly expressed in human liver as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. The presence of insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. Therefore, we suggest that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.